Ben Solomon, Medical Oncologist at Peter MacCallum Cancer Centre, shared on X:
“New standard of care for KRAS G12C mutation positive NSCLC.
Ferdinandos Skoulidis presents Krascendo-1 head to head trial of divarasib vs sotorasib or adagrasib– convincing improving PFS (9.8 m vs 5.7 m, HR 0.58) and OS (17.7m vs 12.0m, HR 0.58).”
You can also read: Krascendo 1 Phase III: Divarasib Significantly Improves Overall Survival and Progression-Free Survival Versus Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC
